首页> 外文OA文献 >A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

【2h】

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

机译：I型试验静脉输注ONYX-015和实体肿瘤患者的嵌入

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J Nemunaitis; N Senzer; S Sarmiento; Y-A Zhang; R Arzaga; B Sands; P Maples; A W Tong;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients [J] . J Nemunaitis, N Senzer, S Sarmiento, Cancer gene therapy . 2007,第11期

机译：实体瘤患者静脉输注ONYX-015和Enbrel的I期试验
2. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion [J] . Conlon Kevin C., Potter E. Lake, Pittaluga Stefania, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第16期

机译：IL15通过连续静脉输注对成年患者在I期试验诱导的巨大肿瘤中的患者诱导的戏剧性NK细胞群扩张
3. 209 Phase I clinical trial in patients with refractory solid tumors: the weekly 24 hour intravenous infusion of aviscumine, a recombinant ribosome-inactivating protein [J] . P.Sch?ffski, I.Breidenbach, O.Bolte, European Journal of Cancer Supplements . 2004,第8期

机译：209难治性实体瘤患者的I期临床试验：每周24小时静脉输注阿维斯卡汀（一种重组核糖体失活蛋白）
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. An open-label dose-escalation safety and pharmacokinetics phase I study of ombrabulin a vascular disrupting agent administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors [O] . H. Murakami, T. Kurata, Y. Onozawa, -1

机译：一项开放性剂量递增安全性和药代动力学I期研究ombrabulin（一种血管破裂剂）每3周对日本晚期实体瘤患者进行30分钟静脉输注
7. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion [O] . Kevin C. Conlon, E. Lake Potter, Stefania Pittaluga, 2019

机译：IL15通过连续静脉输注对成年患者在I期试验诱导的巨大肿瘤中的患者诱导的戏剧性NK细胞群扩张

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

著录项

引文网络

相似文献

相关主题

期刊订阅